N/A
N=20
Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)
Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT05021133 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcome: Primary: Completion of Tele-Navi LCS — 20 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Tele-Navi LCS (Behavioral)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- University of Massachusetts, Worcester
- Primary completion
- Aug 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Completion of Tele-Navi LCS |
20 | — |
| SECONDARY Completion of Follow-up LCS |
10 | — |
Summary
Adherence to annual follow up is critical to achieving mortality benefits and optimizing cost-effectiveness of lung cancer screening (LCS). However, adherence to LCS follow-up in the real world is suboptimal. Using telehealth, the investigators will co-create Tele-Navigation of Lung Cancer Screening with patients and LCS stakeholders as an intervention to promote adherence of follow-up LCS. The investigators will then implement the Tele-Navi LCS intervention to a pilot sample of patients and evaluate its feasibility in the primary care setting. The investigators will measure the number of patient participants who completed Tele-Navi LCS and follow-up LCS within 180 days from Tele-Navi LCS.
Eligibility Criteria
Inclusion Criteria
- Is eligible for LDCT for LCS follow-up
- Has technology to complete study activities (e.g., video call visit)
- English speaker
- Has undergone LCS at UMMH
- Is overdue for LDCT follow-up
Exclusion Criteria
- Has previous diagnosis of lung cancer
- Has active cancer diagnosis
- Is a nursing home or group care resident
- Is pregnant
Data sourced from ClinicalTrials.gov (NCT05021133). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.